https://www.selleckchem.com/pr....oducts/abbv-2222.htm
The impact of different disease stages and treatment for human epidermal growth factor 2 positive (HER2-positive) breast cancer (BC) on work productivity and health-related quality of life (HRQoL) is poorly understood. This was a UK cross-sectional study of 299 adult patients with HER2-positive early or metastatic BC (NCT0309920. Productivity was assessed using the work productivity and activity impairment scale; HRQoL was measured using EuroQol-5 Dimensions-5 levels (EQ-5D-5L), and Functional Assessment of Cancer Therapy Breast (FA
Aimer
Commentaire
Partagez
